George Rodrigues1, Hak Choy2, Jeffrey Bradley3, Kenneth E Rosenzweig4, Jeffrey Bogart5, Walter J Curran6, Elizabeth Gore7, Corey Langer8, Alexander V Louie9, Stephen Lutz10, Mitchell Machtay11, Varun Puri12, Maria Werner-Wasik13, Gregory M M Videtic14. 1. Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada. Electronic address: george.rodrigues@lhsc.on.ca. 2. Department of Radiation Oncology, University of Texas Southwestern, Dallas, Texas. 3. Department of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri. 4. Department of Radiation Oncology, The Icahn School of Medicine at Mount Sinai, New York, New York. 5. Department of Radiation Oncology, State University of New York Upstate Medical University, Syracuse, New York. 6. Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia. 7. Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin. 8. Department of Medical Oncology, University of Pennsylvania, Philadelphia, Pennsylvania. 9. Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada. 10. Department of Radiation Oncology, Blanchard Valley Health System, Findlay, Ohio. 11. Department of Radiation Oncology, UH Case Medical Center, Cleveland, Ohio. 12. Department of Surgery, Washington University School of Medicine, St Louis, Missouri. 13. Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania. 14. Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio.
Abstract
PURPOSE: To provide guidance to physicians and patients with regard to the use of adjuvant external beam radiation therapy (RT) in locally advanced non-small cell lung cancer (LA NSCLC) based on available medical evidence complemented by consensus-based expert opinion. METHODS AND MATERIALS: A panel authorized by the American Society for Radiation Oncology (ASTRO) Board of Directors and Guidelines Subcommittee conducted 2 systematic reviews on the following topics: (1) indications for postoperative adjuvant RT and (2) indications for preoperative neoadjuvant RT. Practice guideline recommendations were approved using an a priori-defined consensus-building methodology supported by ASTRO and approved tools for the grading of evidence quality and the strength of guideline recommendations. RESULTS: For patients who have undergone surgical resection, high-level evidence suggests that use of postoperative RT does not influence survival, but optimizes local control for patients with N2 involvement, and its use in the setting of positive margins or gross primary/nodal residual disease is recommended. No high-level evidence exists for the routine use of preoperative induction chemoradiation therapy; however, modern surgical series and a post-hoc Intergroup 0139 clinical trial analysis suggest that a survival benefit may exist if patients are properly selected and surgical techniques/postoperative care is optimized. CONCLUSIONS: A consensus and evidence-based clinical practice guideline for the adjuvant radiotherapeutic management of LA NSCLC has been created addressing 2 important questions.
PURPOSE: To provide guidance to physicians and patients with regard to the use of adjuvant external beam radiation therapy (RT) in locally advanced non-small cell lung cancer (LA NSCLC) based on available medical evidence complemented by consensus-based expert opinion. METHODS AND MATERIALS: A panel authorized by the American Society for Radiation Oncology (ASTRO) Board of Directors and Guidelines Subcommittee conducted 2 systematic reviews on the following topics: (1) indications for postoperative adjuvant RT and (2) indications for preoperative neoadjuvant RT. Practice guideline recommendations were approved using an a priori-defined consensus-building methodology supported by ASTRO and approved tools for the grading of evidence quality and the strength of guideline recommendations. RESULTS: For patients who have undergone surgical resection, high-level evidence suggests that use of postoperative RT does not influence survival, but optimizes local control for patients with N2 involvement, and its use in the setting of positive margins or gross primary/nodal residual disease is recommended. No high-level evidence exists for the routine use of preoperative induction chemoradiation therapy; however, modern surgical series and a post-hoc Intergroup 0139 clinical trial analysis suggest that a survival benefit may exist if patients are properly selected and surgical techniques/postoperative care is optimized. CONCLUSIONS: A consensus and evidence-based clinical practice guideline for the adjuvant radiotherapeutic management of LA NSCLC has been created addressing 2 important questions.
Authors: Mark R Waddle; Stephen Ko; Margaret M Johnson; Yanyan Lou; Robert C Miller; Anna C Harrell; Daniel M Trifiletti Journal: Transl Lung Cancer Res Date: 2018-04
Authors: J Agulnik; G Kasymjanova; C Pepe; M Hurry; R N Walton; L Sakr; V Cohen; M Lecavalier; D Small Journal: Curr Oncol Date: 2020-10-01 Impact factor: 3.677
Authors: Dustin K Lieu; Li Ding; Elizabeth A David; Sean C Wightman; Scott M Atay; P Michael McFadden; Anthony W Kim Journal: J Thorac Dis Date: 2021-05 Impact factor: 3.005